Burixafor (TG-0054) hydrobromide is a potent CXCR4 antagonist with a pIC50 of 7.4. Burixafor hydrobromide inhibits the binding of CXCL12 to CXCR4, antagonizes CXCL12-induced recruitment of Galpha and beta-arrestin2, and blocks the downstream Galpha-mediated inhibitory effect on cAMP signal transduction. Burixafor hydrobromide mobilizes CD34+ hematopoietic stem/progenitor cells (HSPC) from the bone marrow to the peripheral blood. Burixafor hydrobromide can be used for research on autologous hematopoietic stem cell transplantation (ASCT)[1][2].
Molecular Weight:
769.01
Purity:
98
CAS Number:
[1191450-19-7]
Formula:
C27H51N8O3P.5/2HBr
Target:
CXCR
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted